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Results of experiments evaluating the efficacy of three immunization strategies for the prevention of West
Nile virus (WNV) encephalitis are reported. Immunization strategies evaluated included a killed virus veter-
inary vaccine, a live attenuated chimeric virus vaccine candidate, and passive immunization with WNV-
immune serum; all were tested by using a hamster model of the disease. Each product protected the ani-
mals from clinical illness and death when challenged with a hamster-virulent wild-type WNV strain 1 month
after initial immunization. The live attenuated chimeric virus vaccine candidate induced the highest
humoral antibody responses, as measured by hemagglutination inhibition, complement fixation, and
plaque reduction neutralization tests. Although the duration of protective immunity was not determined in
this study, our preliminary results and the cumulative experience of other virus vaccines suggest that the
live attenuated chimeric virus provides the longest lasting immunity. 
fter the appearance of West Nile virus (WNV) in North
America and the resulting human and equine cases of
encephalitis, considerable efforts have focused on developing
vaccines against this emerging viral pathogen. A number of
different WNV vaccine candidates have been recently
described and are now in various stages of testing (1–4). A for-
malin-inactivated veterinary vaccine (West Nile Virus Vac-
cine, Killed, Fort Dodge Animal Health, Fort Dodge, IA) was
conditionally licensed by the U.S. Department of Agriculture
in August 2001 and has already been used in equines and
exotic zoo birds in some areas of the country. We report the
results of studies evaluating the efficacy of the killed veteri-
nary vaccine, a live attenuated chimeric virus candidate, and
passive immunization with immune serum for preventing
WNV encephalitis in a hamster model of the disease (5,6).
Materials and Methods
Virus, Vaccines, and Immune Serum
The virus used to infect animals in these studies was a sec-
ond Vero cell passage of strain NY385-99, originally isolated
from the liver of a Snowy Owl (Nyctea scandiaca) that died at
the Bronx Zoo during the 1999 WNV epizootic in New York
City (7).  Two different WNV vaccines were evaluated in the
hamster model: West Nile Encephalitis Virus Vaccine (killed),
(Fort Dodge Animal Health, Fort Dodge, IA), a formalin-inac-
tivated whole virus veterinary vaccine, and ChimeriVax–West
Nile virus (Acambis, Inc., Cambridge, MA), a live attenuated
chimeric virus vaccine candidate (1). The immune serum used
in passive immunization experiments was prepared by pooling
convalescent-phase serum samples of six hamsters that were
bled 5 weeks after infection with WNV strain NY385-99. 
Hamsters and Hamster Model
Animals used in these studies were adult (10–11 weeks
old) female hamsters (Mesocricetus auratus) obtained from
Harlan Sprague Dawley, Inc. (Indianapolis, IN). The hamster
model of WNV encephalitis has been described (5,6). After
intraperitoneal inoculation of 104 tissue culture infectious
dose50 (TCID50) of WNV strain NY385-99, fatal encephalitis
developed in approximately 50% of adult hamsters. Animals
were cared for in accordance with the guidelines of the Com-
mittee on Care and Use of Laboratory Animals (Institute of
Laboratory Animal Resources, National Research Council)
under an animal-care protocol approved by the University of
Texas Medical Branch. All work with infected animals was
carried out in biosafety level 3 facilities. 
Immunization Schedule and Challenge with WNV
Hamsters immunized with West Nile Encephalitis Virus
Vaccine (killed) received two intramuscular injections of 0.1 mL
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each, given 3 weeks apart, following manufacturer’s recommen-
dation. Eleven days after the second immunization, the hamsters
were bled to determine their antibody response; each animal
was then inoculated intraperitoneally with 104 TCID50 of WNV
strain NY385-99. After challenge with live virus, the animals
were bled daily for 6 consecutive days to measure the level of
viremia and subsequent immune response. The animals were
observed for another 21 days to determine if any developed
signs of encephalitis or died. 
Two groups of hamsters were inoculated intramuscularly
with the ChimeriVax–WNV vaccine. One group received 106.3
PFU, and the other received 103.3 PFU of the chimeric virus.
Thirty-one and 32 days, respectively, after injection of the
virus, the two groups of hamsters were inoculated intraperito-
neally with 104 TCID50 of WNV strain NY385-99. After chal-
lenge, the animals were bled daily for 6–7 days to measure the
level of viremia and immune response, as described previ-
ously. These hamsters were also observed for 21 additional
days for signs of illness or death. 
Two groups of hamsters also were passively immunized
with different amounts (0.1 mL and 0.5 mL) of hamster WNV-
immune serum, given intramuscularly. One day after passive
immunization, both groups of animals were bled to determine
if detectable titers of WNV hemagglutination inhibition (HI)
antibodies were present in their serum. The animals then were
inoculated intraperitoneally with 104 TCID50 of WNV strain
NY385-99, bled for 7 consecutive days, and observed for
another 21 days, as described previously. 
A group of naïve (control) hamsters was also inoculated
intraperitoneally with the same dosage of WNV strain NY385-
99. Thirty-eight days after infection, 10 of the surviving ani-
mals were bled to determine their antibody response. 
Virus Titration and Antibody Determinations
Serial blood samples from the hamsters were titrated in
microplate cultures of the C6/36 clone of Aedes albopictus
cells (8). The presence or absence of WNV viral antigen,
determined by immunofluorescence, was used as the endpoint.
This technique has been described in detail (5,6). WNV titers
in the blood samples were calculated as the TCID50 per micro-
liter of specimen by the method of Reed and Muench (9). 
Serum antibodies to WNV and Yellow fever virus (YFV)
were measured by HI, complement fixation (CF), and plaque
reduction neutralization (PRN) tests. Antigens for HI and CF
tests were prepared from brains of newborn mice injected
intracerebrally with the respective flaviviruses; these infected
brains were treated by the sucrose-acetone extraction method
(10). Hamster sera were tested by HI at serial twofold dilutions
from 1:20 to 1:5,120 at pH 6.6 (WNV) or 6.4 (YFV) with 4 U
of antigen and a 1:200 dilution of goose erythrocytes, follow-
ing established protocols (10). 
CF tests were performed by a microtechnique (10) with
two full units of guinea pig complement and antigen titers
>1:32. Titers were recorded as the highest dilutions giving +3
or +4 fixation of complement on a scale of 0 to +4. 
PRN tests on hamster serum were performed by a previ-
ously described technique (11) in 24-well, Vero-microplate-
cell cultures, using a fixed virus inoculum (~100 PFU) against
varying serum dilutions (1:10 to 1:20,480). For PRN tests, the
Egypt 101 strain of WNV (12) was used because this strain
produced larger and sharper plaques than NY385-99. Hamster
serum samples were diluted in phosphate-buffered saline, pH
7.4, containing 10% fresh guinea pig serum. Virus inoculum
was mixed with an equal volume of each serum dilution; and
the mixture was incubated overnight at 4°C. The following
day, 50 uL of the serum-virus mixture was injected into Vero
microplate cultures, with two wells per serum dilution. Virus
plaques were read 4 days later; >90% plaque reduction was
used as the endpoint. 
Results
WNV Infection in Naïve Hamsters
The level and duration of viremia, antibody response, and
deaths in naïve (non-immune) adult hamsters after WNV
infection have been described (5,6). Following intraperitoneal
inoculation of 104 TCID50 of WNV strain NY385-99, moder-
ate levels of viremia that persisted for 6 days developed in the
hamsters (Figure). HI antibodies were detected in the animals
as early as day 5, and titers continued to increase through day
7. Initially, HI antibody response in primary WNV infection is
specific; but after 3 or 4 weeks, the antibody pattern becomes
more broadly reactive and serologic cross-reactions occur with
other flavivirus antigens (6). Table 1 shows the HI, CF, and
PRN antibody responses to WNV antigen and virus in 10
naïve adult hamsters that survived infection with the NY385-
99 virus strain. These animals were bled 38 days after infec-
tion. Hamsters who survived infection with wild-type WNV
appeared to have solid immunity 1 month after infection
(Table 1). Convalescent-phase sera from some of these ani-
mals were used to prepare the WNV immune serum used in
the passive immunization experiments described below. 
Figure. Daily mean (plus or minus the standard deviation) virus titers
and hemagglutination inhibition (HI) antibody levels in 10 naïve (control)
hamsters after intraperitoneal inoculation of 104 TCID50 West Nile virus
strain NY385-99.RESEARCH
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WNV Infection in Hamsters Previously 
Immunized with a Killed Vaccine
Table 2 shows the HI, CF, and PRN antibody responses of
nine hamsters 32 days after immunization (2 injections) with
the Fort Dodge WNV killed vaccine. One month after the ini-
tial immunization, eight of nine animals had detectable levels
of HI and CF antibodies; five of nine hamsters had low levels
of WNV-neutralizing antibodies. Six days after challenge with
the wild-type virus, most of the hamsters had an increase
(range two-fold to 32-fold increase) in their HI and CF anti-
body titers, indicating some degree of antigenic stimulation
and possible virus replication. Two of the hamsters had detect-
able levels of viremia after challenge with the wild-type virus
(Table 3). However, none of the animals appeared clinically
ill, and all survived. 
WNV Infection in Hamsters Previously 
Immunized with Live, Attenuated Chimeric Vaccine
Tables 4 and 5 show the antibody responses of hamsters
receiving two different doses (106.3 and 103.3) of ChimeriVax-
WNV vaccine. The results of these two experiments were sim-
ilar. One month after immunization, all animals had detectable
HI, CF, and PRN-antibody titers to WNV. When tested 6–7
days after challenge with the wild-type virus, none of the ani-
mals had a substantial change in antibody titer. WNV was
detected in the blood of one animal on day 2; the titer was
100.7 TCID50/mL (data not shown). None of the animals in
these two groups appeared sick, and all survived. 
WNV Infection in Passively Immunized Hamsters
Two groups of hamsters (A and B) were inoculated with
0.5 mL and 0.1 mL, respectively, of hamster WNV-immune
serum (Table 6). HI antibody titer of the immune serum was
1:1,280; PRN titer was 1:5,120. Twenty-four hours later, the
animals were bled and then injected with the wild-type virus.
When tested 24 hours after receiving WNV-immune serum, all
Table 1. Hemagglutination inhibition, complement fixation, and plaque 
reduction neutralization antibody responses of naïve adult golden 
hamsters that survived West Nile virus infectiona,b
Animal no.
HI antibody titer 
WNV antigen
CF antibody titer 
WNV antigenc
WNV PRN anti-
body titerd
H-8589 1:1280 1:320 1:10,240
H-8590 1:640 1:160 1:10,240
H-8591 1:640 1:320 1:5120
H-8592 1:640 1:80 1:2560
H-8593 1:640 1:160 1:2560
H-8594 1:1280 1:160 1:5120
H-8595 1:1280 1:320 1:10,240
H-8596 1:1280 1:320 >1:20,480
H-8597 1:1280 1:320 1:5120
H-8598 1:1280 1:640 1:2560
aHI, hemagglutination inhibition; CF, complement fixation; PRN, plaque reduction neu-
tralization; WNV, West Nile virus.
bAnimals 38 days after inoculation of virus strain NY385-99 (104.0 tissue culture infec-
tive dose50 given intraperitoneally).
cWNV antigen titer = >1:32.
dHighest serum dilution producing >90% plaque inhibition.
Table 2. WNV antibody response of hamsters after immunization with 
WNV killed virus vaccine (Fort Dodge) and challenge with the NY385-
99 strain of WNVa,b 
Animal no.
HI antibody 
titer
CF antibody 
titer
PRN antibody 
titerc
32 days after Ft. Dodge vaccine
H-8440 1:40 1:40 1:20
H-8441 0d 0< 1 : 1 0
H-8442 1:20 1:40 <1:10
H-8443 1:40 1:40 1:20
H-8445 1:40 1:40 1:20
H-8446 1:20 1:20 1:40
H-8447 1:20 1:20 <1:10
H-8448 1:20 1:20 <1:10
H-8449 1:40 1:20 1:10
6 days after challenge with WNV
H-8440 1:80 1:80 ND
H-8441 1:320 1:160 ND
H-8442 1:40 1:40 ND
H-8443 1:40 1:40 ND
H-8445 1:320 1:160 ND
H-8446 1:80 1:40 ND
H-8447 1:320 1:160 ND
H-8448 1:160 1:80 ND
H-8449 1:160 1:40 ND
aWNV, West Nile virus; HI,  hemagglutination inhibition; CF, complement fixation; 
PRN, plaque reduction neutralization; ND, not done.
b104.0 50% tissue culture infective dose50 given intraperitoneally.
cHighest serum dilution producing >90% plaque inhibition.
d0 = <1:20.
Table 3. Level and duration of viremia in hamsters previously immu-
nized with WNV killed virus vaccine (Fort Dodge) and challenged with 
the NY385-99 strain of WNVa
Animal no.
Postinfection, by day
123 4 56
8440 0b 00 000
8441 0 1.2 3.5 1.3 1.2 0
8442 0 0 0 0 0 0
8443 0 0 0 0 0 0
9445 0 0 0 0 0 0
8446 0 0 0 0 0 0
8447 0 0 0 0 0 0
8448 0 0.7 3.0 4.3 2.3 0
8449 0 0 0 0 0 0
aWNV, West Nile virus.
bVirus titers in blood expressed as log10 50% tissue culture infective dose50/mL of 
blood. 0 = <100.7 TCID50.Emerging Infectious Diseases  •  Vol. 8, No. 12, December 2002 1395
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animals in group A had low but detectable HI antibody titers.
No HI antibodies in group B were detectable after 24 hours.
Seven days after challenge with WNV, one animal in group A
still had detectable HI antibodies. Hamsters in groups A and B
were bled for 6 consecutive days; no virus was detectable in
any of the blood samples (data not shown). All animals in
groups A and B appeared well and survived challenge. The
absence of an antibody response or viremia in the passively
immunized animals suggests that no virus replication occurred
after challenge with WNV. 
Discussion
Each of the three immunization products evaluated in this
study (killed whole virus vaccine, live attenuated chimeric
virus vaccine, and passive immunization with immune serum)
protected hamsters from clinical encephalitis and death upon
subsequent challenge with the virulent wild-type WNV strain
NY385-99. In contrast, fatal encephalitis developed in approx-
imately 50% of naïve hamsters inoculated with the same virus
dose (5). One obvious deficiency of our study was that the
duration of protection induced by each immunization product
was not determined. Determining the duration of protection is
difficult with a relatively short-lived (approximately 2 yrs)
animal such as a hamster; such studies are more meaningful
when conducted by using longer-lived species such as horses
or humans. Nonetheless, the general experience with other live
and inactivated vaccines and the use of immune globulin for
prevention of viral diseases offers some clue as to the advan-
tages and disadvantages of the three approaches for preventing
WNV encephalitis (13,14). 
Passive Immunization with WNV Immune Globulin
Hamsters inoculated with WNV immune serum (0.5 mL
and 0.1 mL) appeared to be completely protected when chal-
lenged with the wild-type virus 24 hours after passive immuni-
zation (Table 6). No virus was detected in the animals’ blood
after challenge, and HI antibodies to WNV viral antigen did
not develop. Immune globulins present in the WNV-immune
serum probably inhibited virus replication; consequently,
insufficient antigenic mass existed in the animals to stimulate
an antibody response. One advantage of passive immunization
with WNV-immune globulins is that the protective effect is
almost immediate (<24 hours in the case of the hamsters in our
experiment). Passive immunization with WNV-immune glob-
Table 4. Antibody response of adult golden hamsters to intramuscular inoculation of 1.8 X 106 of ChimeriVax–WNV and subsequent challenge 
with WNV (104.0 TCID50 given intraperitoneally)a
Animal no.
HI antibody titer CF antibody titer WNV PRN antibody titerb
YFV antigen WNV antigen YFV antigen WNV antigen
31 days after ChimeriVax-WNV
H-8183 1:40 1:160 0c 01 : 1 6 0
H-8184 1:40 1:160 0 ND 1:160
H-8185 1:40 1:160 0 1:20 1:640
H-8186 1:80 1:320 0 1:40 1:320
H-8187 1:40 1:160 0 1:20 >1:640
H-8188 1:40 1:160 0 1:20 1:640
H-8189 1:80 1:320 0 1:40 1:640
H-8190 1:40 1:160 0 1:20 1:320
H-8191 1:80 1:160 0 1:20 1:80
H-8192 1:40 1:160 0 1:40 1:80
6 days after challenge with WNV
H-8183 1:20 1:160 0 0 ND
H-8184 1:40 1:160 0 1:40 ND
H-8185 1:20 1:160 0 1:20 ND
H-8186 1:80 1:320 0 1:40 ND
H-8187 1:20 1:160 0 1:20 ND
H-8188 1:40 1:160 0 1:20 ND
H-8189 1:80 1:320 0 1:40 ND
H-8190 1:40 1:320 0 1:40 ND
H-8191 1:40 1:320 0 1:20 ND
H-8192 1:40 1:160 0 1:20 ND
aWNV, West Nile virus; HI, hemagglutination inhibition; CF, complement fixation; PRN, plaque reduction neutralization; YFV, Yellow fever virus; ND, not done.
bHighest serum dilution producing >90% plaque inhibition.
c0 = <1:20.RESEARCH
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ulins might be desirable when rapid, temporary protection
against the virus is needed or when a person with a compro-
mised immune system requires protection. The major disad-
vantage of passive immunity acquired from immune globulins
is the relatively short period of protection (13).
Inactivated WNV Vaccine
Most hamsters immunized with the Fort Dodge killed
WNV vaccine had low levels of HI, CF, and PRN antibodies
after two injections (Table 2). None of the animals that
received the killed vaccine appeared clinically ill or died after
challenge with the wild-type WNV. However, six of the nine
hamsters had a substantial increase in their HI antibody titer
after challenge with the wild-type virus; two of the nine ani-
mals subsequently had detectable viremia (Table 3). These
data suggest that the immune response to the killed vaccine
was insufficient to completely inhibit virus replication and that
some degree of virus replication occurred after challenge with
the wild-type virus. 
The Fort Dodge WNV veterinary vaccine used in this study
is a commercially available formalin-inactivated whole virion
preparation that has received conditional approval from the U.S.
Department of Agriculture for use in horses. The first WNV
vaccine approved for use in the United States, its substrate and
degree of purification are not public information. Duration of
protection with this vaccine is also unknown, although the man-
ufacturer recommends that horses be immunized annually. 
The major advantage of killed vaccines is their safety; the
disadvantages are that they often require multiple doses to
elicit and sustain an effective immune response and that the
immune response may be imbalanced, leading to subsequent
potentiation of the disease (14,15). However, highly purified
killed-virus vaccines have been used effectively in persons for
the prevention of Japanese encephalitis virus and Tick-borne
encephalitis virus (16,17). 
Live, Attenuated Chimeric WNV
Hamsters receiving both doses (106.3 or 103.3 PFU) of the
ChimeriVax-WNV had good HI and PRN-antibody responses
to WNV, when tested 1 month after immunization (Tables 4
and 5). One animal (H-8183) did not develop CF antibodies
after immunization, and two other hamsters were not tested.
Notably, CF antibodies to WNV viral antigen developed in
most of the hamsters after vaccination with the ChimeriVax-
WNV, although humans without previous flavivirus exposure
generally do not develop CF antibodies after administration of
the 17D vaccine (18). The ChimeriVax technology platform
uses YFV 17D as a live vector for envelope genes of WNV (1). 
Six and 7 days after challenge with the wild-type virus, we
found no change in HI or CF titers of the animals previously
immunized with the ChimeriVax-WNV (Tables 4 and 5). PRN
titers were not tested after challenge. WNV was detected in the
blood of a single animal on day 2, although WNV antibody
titers did not increase in the blood of this hamster 6 days after
Table 5. Antibody response of adult golden hamsters to intramuscular inoculation of 1.8 X 103 of ChimeriVax-WNV and WNV104.0 TCID50 given 
intraperitoneallya
Animal no. HI antibody titer CF antibody titer WNV PRN antibody titerb
YFV antigen WNV antigen YFV antigen WNV antigen
32 days after ChimeriVax-WNV
H-8322 1:40 1:160 0c 1:20 1:320
H-8323 1:20 1:80 0 1:40 1:160
H-8324 1:80 1:320 1:20 1:80 1:160
H-8325 1:40 1:320 0 1:80 ≥  1:640
H-8326 1:40 1:320 0 1:80 1:320
H-8327 1:40 1:320 ND ND 1:320
H-8328 1:80 1:320 1:20 1:80 1:80
H-8329 1:40 1:320 0 1:80 1:80
7 days after challenge with WNV
H-8322 1:40 1:320 0 1:20 ND
H-8323 1:40 1:160 0 1:20 ND
H-8324 1:80 1:320 0 1:40 ND
H-8325 1:80 1:320 0 1:80 ND
H-8326 1:80 1:320 0 1:40 ND
H-8327 1:40 1:160 0 1:20 ND
H-8328 1:80 1:320 0 1:40 ND
H-8329 1:40 1:320 0 1:80 ND
aWNV, West Nile virus; HI, hemagglutination inhibition; CF, complement fixation; PRN, plaque reduction neutralization; YFV, Yellow fever virus; ND, not done.
bHighest serum dilution producing >90% plaque inhibition.  
c0 = <1:20.Emerging Infectious Diseases  •  Vol. 8, No. 12, December 2002 1397
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challenge. These data suggest that minimal WNV replication
occurred in the animals immunized with the chimeric virus
when challenged with the wild-type virus. The levels of PRN
antibodies present in ChimeriVax-WNV–immunized hamsters
also suggest that the protection would be long lasting. 
The major advantages of live attenuated virus vaccines are
that they induce a more balanced immune response and that the
resulting immunity is longer lasting than with killed vaccines or
immune globulins (13–15). Major concerns with a live WNV
vaccine are related to safety: 1) a potential vaccine might con-
tain adventitious agents; 2) the vaccine virus might cause ill-
ness in some recipients or lose attenuation during manufacture
or replication; and 3) stability. The second and third concerns
are currently being investigated and addressed; results will be
reported in subsequent publications. However, on balance, the
ChimeriVax-WNV candidate vaccine appears to be quite effec-
tive in preventing WNV encephalitis, on the basis of our com-
parative studies in a hamster model of the disease. 
Acknowledgments
The authors thank Dora Salinas for help in preparing the manu-
script. 
This work was supported by grants AI-10984 and AI-50175 from
the National Institutes of Health and by contract U50/CCU620541
from the Centers of Disease Control and Prevention. 
Juan Arroyo and Thomas P. Monath are employees of Acambis,
Inc., which developed the ChimeriVax-West Nile vaccine candidate. 
References
  1. Monath TP. Prospects for the development of a vaccine against the West
Nile virus. Ann NY Acad Sci 2001;951:1–12. 
  2. Davis BS, Chang G-JJ, Cropp B, Roehrig JT, Martin DA, Mitchell CJ, et
al. West Nile virus recombinant DNA vaccine protects mouse and horse
from virus challenge and expresses in vitro a noninfectious recombinant
antigen that can be used in enzyme-linked immunosorbent assays. J Virol
2001;75:4040–7. 
    3. Lustig S, Olshevsky U, Ben-Nathan D, Lachmi BE, Malkinson M,
Kobiler D, et al. A live, attenuated West Nile virus strain as a potential
veterinary vaccine. Viral Immunol 2000;13:401–10. 
  4. Pletnev AG, Putnak R, Speicher J, Wagar EJ, Vaughn DW. West Nile
virus/dengue type 4 virus chimeras that are reduced in neurovirulence and
peripheral virulence without loss of immunogenicity or protective effi-
cacy. Proc Natl Acad Sci U S A 2002;99:3036–41. 
  5. Xiao S-Y, Guzman H, Zhang H, Travassos da APA, Tesh, RB. West Nile
virus infection in the golden hamster (Mesocricetus auratus): a model for
West Nile encephalitis. Emerg Infect Dis 2001;7:714–21. 
    6. Tesh RB, Travassos da Rosa APA, Guzman H, Araujo TP, Xiao-SY.
Immunization with heterologous flaviviruses protective against fatal West
Nile encephalitis. Emerg Infect Dis 2002;8:245–51. 
  7. Steele KE, Linn MJ, Schoepp RJ, Komar N, Geisbert TW, Manduca RM,
et al. Pathology of fatal West Nile virus infections in native and exotic
birds during the 1999 outbreak in New York City, New York. Vet Pathol
2000;37:208–24. 
  8. Tesh RB. A method for the isolation of dengue viruses, using mosquito
cell cultures. Am J Trop Med Hyg 1979;28:1053–9. 
  9. Reed LJ, Muench H. A simple method for estimating fifty percent end-
points. Am J Hyg 1938;27:493–7. 
10. Beaty BJ, Calisher CH, Shope RE. Arboviruses. In: Lennette EH, Len-
nette DA, Lennette ET, editors. Diagnostic procedures for viral, rickett-
sial and chlamydial infections. 7th ed. Washington: American Public
Health Association; 1995. p. 189–212. 
11. Bartelloni PJ, Tesh RB. Clinical and serologic responses of volunteers
infected with phlebotomus fever virus (Sicilian type). Am J Trop Med
Hyg 1976;25:456–62. 
12. Melnick JL, Paul JR, Riordan JT, Barnett VH, Goldblum N, Zabin E. Iso-
lation from human serum in Egypt of a virus apparently identical to West
Nile virus. Proc Soc Exp Biol Med 1951;77:661–5. 
13. Stiehm ER. Passive immunization. In: Feigin RD, Cherry JD, editors.
Textbook of pediatric infectious diseases. 4th ed. Vol. 2. Philadelphia:
WB Saunders Company; 1998. p. 2769–802. 
14. Murphy BR, Chanock RM. Immunization against viral diseases. In:
Knipe DM, Howley PM, Griffin DE, Martin MA, Lamb RA, Roizman B,
et al., editors. Fields virology. 4th ed., Vol. 1. Philadelphia: Lippincott
Williams and Wilkins; 2001. p. 435–67. 
15. Watson JC, Peter G. General immunization practices. In: Plotkin SA,
Orenstein WA, editors. Vaccines. 3rd ed. Philadelphia: WB Saunders
Company; 1999. p. 47–73. 
16. Tsai TF, Chang G-JJ, Yu YX. Japanese encephalitis vaccines. In: Plotkin
SA, Orenstein WA, editors. Vaccines. 3rd ed. Philadelphia: WB Saunders
Company; 1999. p. 672–710. 
17. Barrett PN, Dorner F, Plotkin SA. Tick-borne encephalitis vaccine. In:
Plotkin SA, Orenstein WA, editors. Vaccines. 3rd ed. Philadelphia: WB
Saunders Company; 1999. p. 767–80. 
18. Monath TP. Yellow fever. In: Plotkin SA, Orenstein WA, editors. Vac-
cines. 3rd ed. Philadelphia: WB Saunders Company; 1999. p. 815–80. 
Address for correspondence: Robert B. Tesh, Department of Pathology, Uni-
versity of Texas Medical Branch, 301 University Boulevard, Galveston, TX
77555-0609, USA; fax: 409-747-2429; e-mail: rtesh@utmb.edu
Table 6. WNV hemagglutination inhibition antibody titers in adult ham-
sters 24 h after inoculation (passive immunization) with WNV immune 
serum, and 7 days later after challenge with WNV (104.0 TCID50 given 
intraperitoneally)a
Hamster no. 24 h after passive 
immunization
7 days after challenge 
with WNV
Group A – received 0.5 mL WNV immune serum
H-8126 1:40b 0
H-8127 1:20 0
H-8128 1:20 0
H-8129 1:20 0
H-8130 1:20 0
H-8138 1:40 0
H-8139 1:40 1:10
Group B – received 0.1 mL WNV immune serum)
H-8131 0 0
H-8132 0 0
H-8133 0 0
H-8134 0 0
H-8135 0 0
H-8136 0 0
H-8137 0 0
aWNV, West Nile virus.
bHemagglutination inhibition antibody titer. 0 = <1:10.